Biosight Presents Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) in an Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Ads

You May Also Like

Allscripts to deliver anesthesia solution across SingHealth healthcare institutions

SINGAPORE, May 23, 2018 (GLOBE NEWSWIRE) -- Singapore’s largest public healthcare group, SingHealth, has ...

Allscripts closes acquisition of McKesson’s Enterprise Information Solutions business

CHICAGO, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ:MDRX), a global leader in healthcare ...

NanoVibronix Provides Business Update for the Second Quarter of 2018

Revenue increases 153% for the second quarter of 2018 ELMSFORD, N.Y., Aug. 16, 2018 ...